No Depression (PHQ-9 < 5) n = 2040 | Depression (PHQ-9 ≥ 10) n = 248 | Mild depression (PHQ-9 = 5–9) n = 1101 | |
---|---|---|---|
Women, % (n) | 42.6% (870) | 60.1% (149) | 57.2% (630) |
postmenopausal Women, % (n) | 28.7% (586) | 41.1% (102) | 39.7% (436) |
Age in years, mean ± sd | 55.2 ± 10.9 | 53.2 ± 10.5 | 55.1 ± 10.9 |
Socioeconomic status (SES) (3 = lowest SES, 21 highest SES), mean ± sd | 13.20 ± 4.41 | 11.68 ± 4.12 | 12.04 ± 4.29 |
Partnership, % (n) | 85.8% (1751) | 72.6% (180) | 79.5% (873) |
PHQ-9, median (IQR) | 2.00 (1.00/3.00) | 11.00 (10.00/13.00) | 6.00 (5.00/7.00) |
Somatic symptom dimension of depression | 1.00 (0/2.00) | 6.00 (5.00/7.00) | 3.00(2.00/4.00) |
Cognitive symptom dimension of depression | 0 (0/1.00) | 6.00(4.00/7.00) | 2.00(1.00/3.00) |
GAD-2, median (IQR) | 0 (0/1.00) | 2.00 (2.00/4.00) | 1.00 (0/2.00) |
History of depression, % (n) | / | 44.0% (109) | 23.6% (259) |
History of suicide attempt, % (n) | 0.8% (13) | 12.4% (23) | 3.6% (32) |
History of any anxiety disorder, % (n) | / | 22.2% (55) | 14.3% (157) |
Depression (PHQ-9 ≥ 10) at the 5 –year follow-up | 2.4% (42) | 52.9% (100) | 11.8% (108) |
Psychiatric medication | |||
Antidepressants, % (n) | / | 18.1% (45) | 10.7% (117) |
Antipsychotics, % (n) | / | 2.4% (6) | 1.6% (17) |
Anxiolytics, % (n) | / | 4.0% (10) | 2.8% (31) |
Hypnotics and sedatives, % (n) | / | 4.0% (10) | 3.6% (39) |
Physical Disease | |||
Diabetes mellitus, % (n) | 8.7% (176) | 12.2% (30) | 8.6% (95) |
Arterial Hypertension, % (n) | 51.9% (1058) | 46.4% (115) | 47.0% (518) |
Dyslipidemia, % (n) | 34.6% (706) | 40.7% (101) | 33.9% (372) |
Peripheral artery disease, % (n) | 3.7% (76) | 5.6% (14) | 5.1% (55) |
Coronary artery disease, % (n) | 3.5% (70) | 5.7% (14) | 5.4% (58) |
Chronic heart failure, % (n) | 1.4% (28) | 1.6% (4) | 1.2% (13) |
Chronic obstructive pulmonary disease, % (n) | 3.7% (75) | 5.6% (14) | 5.8% (64) |
Chronic liver disease, % (n) | 0.8% (16) | 1.2% (3) | 0.6% (7) |
Chronic kidney disease,, % (n) | 0.5% (11) | 0.8% (2) | 1.2% (13) |
Cancer, % (n) | 8.4% (171) | 9.7% (24) | 10.4% (114) |
Arthritis, % (n) | 4.1% (83) | 8.5% (21) | 5.7% (63) |
Lifestyle factors | |||
Smoking, % (n) | 17.5% (357) | 27.4% (68) | 20.3% (223) |
Physical activity score [in 1000] | 7.12 (4.81/9.39) | 7.13 (5.01/9.25) | 7.04 (4.97/9.50) |
Alcohol abuse [24/12 g/d], % (n) | 23.9% (488) | 22.6% (56) | 24.8% (273) |
Obesity, % (n) | 22.1% (450) | 25.4% (63) | 25.0% (275) |
Biomarkers | |||
C-Reactive Protein (CRP, mg/L) | 1.60 (0.50/2.90) | 1.80 (1.10/3.50) | 1.60 (1.00/3.20) |
Insulin resistance (HOMA-IR) | 1.75 (1.25/2.58) | 1.76 (1.23/2.58) | 1.76 (1.25/2.53) |
Cholesterol [mmol/L] | 224.2 ± 41.3 | 224.2 ± 43.9 | 224.4 ± 41.7 |
Systolic blood pressure [mmHg] | 133.4 ± 18.0 | 129.6 ± 16.0 | 130.2 ± 17.3 |
Heart rate [beats per minute] | 68.1 ± 10.9 | 68.1 ± 10.6 | 68.7 ± 10.7 |